CSF1R and neoplasm: Our previous study reported that intraperitoneal administration of CSF-1R inhibitor pexidartinib can partially restore docetaxel sensitivity in both the subcutaneous xenograft mouse model from MyC-CaP cells and orthotopic model with CWR22Rv1 and significantly attenuate the growth of primary tumor and achieve longer survival in xenograft mice.